Regulator
Wandercraft said the FDA cleared Eve, a self-balancing exoskeleton for personal use, for adults with spinal cord injuries at any level, used with a trained companion.
A regulator's decision · Company-reported · Sets Medical exoskeletons's stage
What the source says
“the FDA has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility.”
What it means
Medical exoskeletons, from Lifeward (ReWalk), Wandercraft, Ekso Bionics (owned by Wandercraft since Oct 2026), is at stage 5 of 5 on our ladder: regulator-cleared or mass market. This event is one of the milestones that placed it there. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: A staff member rides along, ready to stop it.
More on Medical exoskeletons
- Wandercraft bought Ekso Bionics from ChronoScale and said it would keep supporting Atalante X, EksoNR, Eve and Indego Personal. The price was not disclosed.
- Ekso's parent company, renamed ChronoScale and moving into cloud computing, said it would sell the Ekso exoskeleton business.
- The FDA cleared the ReWalk 7 Personal Exoskeleton from Lifeward (510(k) K241822) for indoor and outdoor walking, including stairs and curbs.
- Medicare set a payment rate for personal exoskeletons for home use, starting with the ReWalk Personal and the Indego Personal.
- Ekso Bionics bought the Indego exoskeleton business from Parker Hannifin for $10 million.
- The FDA cleared the Ekso GT for use in rehab centres with people who have had a stroke or a spinal cord injury.